Presentation and Outcomes After Medical and Surgical Treatment Versus Medical Treatment Alone of Spontaneous Infectious Spondylodiscitis: A Systematic Literature Review and Meta-Analysis

Study Design: Systematic literature review. Objectives: The aims of this study were to (1) describe the clinical features, disabilities, and incidence of neurologic deficits of pyogenic spondylodiscitis prior to treatment and (2) compare the functional outcomes between patients who underwent medical treatment alone or in combination with surgery for pyogenic spondylodiscitis. Methods: A systematic literature review was performed using PubMed according to PRISMA guidelines. No year restriction was put in place. Statistical analysis of pooled data, when documented in the original report (ie, number of patients with desired variable and number of patients evaluated), was conducted to determine the most common presenting symptoms, incidence of pre- and postoperative neurologic deficits, associated comorbidities, infectious pathogens, approach for surgery when performed, and duration of hospitalization. Outcomes data, including return to work status, resolution of back pain, and functional recovery were also pooled among all studies and surgery-specific studies alone. Meta-analysis of studies with subgroup analysis of pain-free outcome in surgical and medical patients was performed. Results: Fifty of 1286 studies were included, comprising 4173 patients undergoing either medical treatment alone or in combination with surgery. Back pain was the most common presenting symptom, reported in 91% of patients. Neurologic deficit was noted in 31% of patients. Staphylococcus aureus was the most commonly reported pathogen, seen in 35% of reported cases. Decompression and fusion was the most commonly reported surgical procedure, performed in 80% of the surgically treated patients. Combined anterior-posterior procedures and staged surgeries were performed in 33% and 26% of surgeries, respectively. The meta-analysis comparing visual analog scale score at follow-up was superior among patients receiving surgery over medical treatment alone (mean difference −0.61, CI −0.90 to −0.25), while meta-analysis comparing freedom from pain in patients receiving medical treatment alone versus combined medical and surgical treatment demonstrated superior pain-free outcomes among surgical series (odds ratio 5.35, CI 2.27-12.60, P < .001), but was subject to heterogeneity among studies ( I2 = 56%, P = .13). Among all patients, freedom from pain was achieved in 79% of patients, and an excellent outcome was achieved in 73% of patients. Conclusion: Medical management remains first-line treatment of infectious pyogenic spondylodiscitis. Surgery may be indicated for progressive pain, persistent infection on imaging, deformity or neurologic deficits. If surgery is required, reported literature shows potential for significant pain reduction, improved neurologic function and a high number of patients returning to a normal functional/work status.

Download Full-text

Outcome of conservative and surgical treatment of pyogenic spondylodiscitis: a systematic literature review

European Spine Journal ◽

10.1007/s00586-015-4318-y ◽

2015 ◽

Vol 25 (4) ◽

pp. 983-999 ◽

Cited By ~ 62

Author(s):

J. P. H. J. Rutges ◽

D. H. Kempen ◽

M. van Dijk ◽

F. C. Oner

Keyword(s):

Surgical Treatment ◽

Literature Review ◽

Systematic Literature Review ◽

Pyogenic Spondylodiscitis ◽

Conservative And Surgical Treatment

Download Full-text

Antibiotic use during end-of-life care: A systematic literature review and meta-analysis

Infection Control and Hospital Epidemiology ◽

10.1017/ice.2020.1241 ◽

2020 ◽

pp. 1-7

Author(s):

Alexandre R. Marra ◽

Mireia Puig-Asensio ◽

Erin Balkenende ◽

Daniel J. Livorsi ◽

Michihiko Goto ◽

...

Keyword(s):

Literature Review ◽

End Of Life ◽

Systematic Literature Review ◽

Meta Analysis ◽

Antibiotic Use ◽

Advanced Dementia ◽

Inclusion Criteria ◽

Number Of Patients ◽

Days Of Therapy ◽

Eol Care

Abstract Background: We performed a systematic literature review and meta-analysis measuring the burden of antibiotic use during end-of-life (EOL) care. Methods: We searched PubMed, CINAHL (EBSCO platform), and Embase (Elsevier platform), through July 2019 for studies with the following inclusion criteria in the initial analysis: antibiotic use in the EOL care patients (advanced dementia, cancer, organ failure, frailty or multi-morbidity). If the number of patients in palliative care consultation (PCC) was available, antibiotic use data were pooled to compare the proportion of patients who received antibiotics under PCC compared to those not receiving PCC. Random-effect models were used to obtain pooled mean differences, and heterogeneity was assessed using the I2 value. Results: Overall, 72 studies met the inclusion criteria and were included in the final review: 22 EOL studies included only patients with cancer; 17 studies included only patients with advanced dementia; and 33 studies included “mixed populations” of EOL patients. Although few studies reported antibiotic using standard metrics (eg, days of therapy), 48 of 72 studies (66.7%) reported antibiotic use in >50% of all patients. When the 3 studies that evaluated antibiotic use in PCC were pooled together, patients under PCC was more likely to receive antibiotics compared to patients not under PCC (pooled odds ratio, 1.73; 95% CI, 1.02–2.93). Conclusions: Future studies are needed to evaluate the benefits and harms of using antibiotics for patients during EOL care in diverse patient populations.

Download Full-text

The impact of smoking on prevalence of psoriasis and psoriatic arthritis

Rheumatology ◽

10.1093/rheumatology/keaa179 ◽

2020 ◽

Vol 59 (10) ◽

pp. 2695-2710 ◽

Cited By ~ 2

Author(s):

Ummugulsum Gazel ◽

Gizem Ayan ◽

Dilek Solmaz ◽

Servet Akar ◽

Sibel Z Aydin

Keyword(s):

Psoriatic Arthritis ◽

General Population ◽

Literature Review ◽

Systematic Literature Review ◽

Past History ◽

Meta Analysis ◽

Cochrane Central Register ◽

Central Register ◽

Number Of Patients ◽

The Impact

Abstract Objectives In this systematic literature review and meta-analysis, we aimed to investigate the impact of cigarette smoking on the prevalence and incidence of psoriasis and psoriatic arthritis (PsA). Method We performed a systematic literature review using the MEDLINE, EMBASE and Cochrane Central Register databases. The literature included publications from January 1980 to July 2019. The studies that provided clear information on the number of patients with ever smoking data were included in the meta-analysis. Results The systematic literature review identified 52 and 24 articles for the prevalence of smoking in psoriasis and PsA, respectively. Of these, 16 articles on psoriasis and three and four (general population and psoriasis, respectively) articles on PsA met the criteria and were included in the meta-analysis. The prevalence of ever smoking was increased in psoriasis compared with the general population (OR: 1.84; 95% CI: 1.4, 2.3). For PsA the prevalence of ever smoking was reduced in psoriasis patients (OR: 0.70; 95% CI: 0.60, 0.81), but not changed compared with the general population (OR: 1.10; 95% CI: 0.92, 1.32). Conclusion This meta-analysis showed that ever smoking increases the risk of psoriasis in the general population, but may reduce the risk of PsA in psoriasis patients. The latter may be also due to the collider effect. Whether smoking cessation neutralizes the risk of developing psoriasis requires a well-defined smoking data collection for the past history and this is currently unavailable in the literature.

Download Full-text

Modic changes—Their associations with low back pain and activity limitation: A systematic literature review and meta-analysis

PLoS ONE ◽

10.1371/journal.pone.0200677 ◽

2018 ◽

Vol 13 (8) ◽

pp. e0200677 ◽

Cited By ~ 28

Author(s):

Christofer Herlin ◽

Per Kjaer ◽

Ansgar Espeland ◽

Jan Sture Skouen ◽

Charlotte Leboeuf-Yde ◽

...

Keyword(s):

Low Back Pain ◽

Back Pain ◽

Literature Review ◽

Systematic Literature Review ◽

Meta Analysis ◽

Modic Changes ◽

Activity Limitation ◽

Low Back

Download Full-text

A Systematic Literature Review and Meta-Analysis of the Incidence of Serious or Severe Hypersensitivity Reactions after Administration of Ferric Derisomaltose and Ferric Carboxymaltose

Blood ◽

10.1182/blood-2021-148388 ◽

2021 ◽

Vol 138 (Supplement 1) ◽

pp. 4157-4157

Author(s):

Patrick Biggar ◽

Nicholas Kennedy ◽

Johannes Pöhlmann ◽

Richard F Pollock-Wilkins

Keyword(s):

Iron Deficiency ◽

Literature Review ◽

Systematic Literature Review ◽

Meta Analysis ◽

Deficiency Anemia ◽

Ferric Carboxymaltose ◽

Hypersensitivity Reactions ◽

Active Comparator ◽

Number Of Patients ◽

Iv Iron

Abstract Background and Aims Intravenous (IV) iron is the preferred treatment for patients with iron deficiency (ID) and iron deficiency anemia (IDA) in a variety of clinical situations. Although uncommon, administration of modern IV iron formulations can result in hypersensitivity reactions and, very rarely, anaphylactic reactions. The objective of the present study was to systematically review the literature to identify and analyze data on the incidence of serious or severe hypersensitivity reactions (HSRs) after administration of different IV iron formulations. Methods A prospectively-registered systematic literature review (SLR) was conducted to identify prospective, active comparator randomized controlled trials (RCTs) comparing ferric derisomaltose (FDI) (also known as iron isomaltoside 1000) or ferric carboxymaltose (FCM) with other IV iron formulations or oral iron. The primary endpoint was the incidence of serious or severe hypersensitivity reactions occurring on the day or day after dosing of IV iron, based on pre-specified terms (MedDRA classification). Results Data were obtained from ten prospective, active comparator RCTs of FDI (N=3,474) and seven prospective, active comparator RCTs of FCM (N=2,683), two of which were head-to-head comparisons of FDI and FCM. The trials enrolled a total of 10,467 patients, of whom 6,157 were treated with either FDI or FCM. The number of patients experiencing any serious or severe hypersensitivity reactions was 5/3474 with FDI (0.14%) versus 29/2683 (1.08%) with FCM; Bayesian inference of proportions showed the reaction rates to be significantly lower with FDI relative to FCM (Figure). Conclusions To our knowledge, the present analysis represents the first SLR and meta-analysis of the incidence of serious or severe HSRs after administration of FDI vs FCM based on pre-specified MedDRA terms. The SLR conducted for the present meta-analysis, identified 15 prospective, head-to-head RCTs including 10,467 patients, of whom 3,474 and 2,683 were treated with FDI and FCM, respectively. The analysis demonstrated that serious or severe hypersensitivity reactions were uncommon with the newer high-dose IV iron formulations; and showed a significantly lower incidence of serious or severe hypersensitivity reactions with FDI compared to FCM. Figure 1 Figure 1. Disclosures Biggar: Vifor-Fresenius: Consultancy; Pharmacosmos: Consultancy; Medice: Consultancy. Pöhlmann: Pharmacosmos A/S: Consultancy. Pollock-Wilkins: Pharmacosmos A/S: Consultancy.

Download Full-text

POS1078 CURRENT REGISTRIES IN PSA DO NOT WELL REFLECT THE PROFILES OF PATIENTS WITH PsA BECAUSE THEY ORIGINATE IN SIMILAR COUNTRIES: A SYSTEMATIC LITERATURE REVIEW OF 27 REGISTRIES, OR 16183 PATIENTS

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2021-eular.3097 ◽

2021 ◽

Vol 80 (Suppl 1) ◽

pp. 818.1-818

Author(s):

G. S. Moysidou ◽

K. Aouad ◽

A. Rakotozafiarison ◽

B. Fautrel ◽

L. Gossec

Keyword(s):

Systematic Review ◽

Psoriatic Arthritis ◽

Literature Review ◽

Diagnostic Criteria ◽

Systematic Literature Review ◽

Disease Duration ◽

Meta Analysis ◽

Weighted Mean ◽

Real World Data ◽

Number Of Patients

Background:Psoriatic arthritis (PsA) is a multidimensional inflammatory disease with a great geographic variability and a global average prevalence estimated at 133 every 100,000 subjects according to a recent systematic review and meta-analysis (1). Registries and cohorts reflect more closely real-world data than randomized controlled trials (RCTS) and may indicate ongoing interest of each country on PsA.Objectives:The purpose of this study is to assess how recent registries and PsA related cohorts reflect its worldwide prevalence.Methods:A systematic literature review was performed in Pubmed Medline (PROSPEROCRD42020175745) to identify all articles reporting on either registries or longitudinal cohorts in PsA, published between 2010 and March 2020. Registries centered on drugs or not PsA-specific, trials and long term extension studies were excluded. The data collection comprised registries’ and cohorts’ originating countries, patient characteristics and the clinical outcome measures reported. Statistics were descriptive.Results:Of 673 articles, 73 were relevant for analysis, corresponding to 27 registries or PsA specific cohorts, with the participation of 30 countries. The overall number of patients was 16,183 with a mean of 599 per study. Overall, 50.1% were men, weighted mean age was 50,6 years and weighted mean disease duration was 6.9 years.Most of the registries were based in Europe (67%) or North America (26%) whereas Africa was underrepresented (Figure 1). USA was the most represented country participating in 6 registries. Mean age and mean disease duration were shorter in international registries (Table 1). Caspar diagnostic criteria were the most frequently used, mainly in the national registries (86,4%), whereas the use of diagnostic criteria was more heterogenous in the international registries.Conclusion:Recent registries and PsA specific cohorts do not cover the worldwide spectrum of the disease.References:[1]Scotti L, Franchi M, Marchesoni A, Corrao G. Prevalence and incidence of psoriatic arthritis: A systematic review and meta-analysis. Semin Arthritis Rheum. 2018 Aug;48(1):28-34Table 1.Description of 27 ongoing PsA registries or PsA cohorts, comparing nationwide and international registriesNATIONWIDE REGISTRIES (N=22)INTERNATIONAL REGISTRIES (N=5)WOMEN (%) 49,4 50,8MEAN AGE, WEIGTHED (YEARS) 52,32 48,09MEAN DISEASE DURATION, WEIGHTED (YEARS) 8,59 5,86CASPAR DIAGNOSTIC CRITERIA (%) 86,4 40Figure 1.Geographical distribution of PsA registriesDisclosure of Interests:None declared.

Download Full-text